Mucosal leishmaniasis (ML) is mostly associated with Leishmania braziliensis; however, a few cases of Leishmania tropica induced mucocutaneous leishmaniasis have been reported. The standard treatment for leishmaniasis is pentavalent antimonials, but several other drugs for resistant cases have been proposed including amphotericin and miltefosine. Here we present a case of multiple treatment resistant mucocutaneous leishmaniasis with nasal involvement caused by L. tropica; cure was not achieved by multiple treatments and was eventually improved by adding thalidomide to Meglumine Antimoniate (Glucantime). To the best of our knowledge use of thalidomide in humans for leishmaniasis treatment is reported here for the first time.

中文翻译：

---

在难治性人为性粘膜皮肤利什曼病的情况下，将沙利度胺添加到葡甲胺锑酸盐中成功治疗。

粘膜利什曼病（ML）主要与巴西利什曼原虫有关。然而，已经报道了几例热带利什曼原虫引起的粘膜皮肤利什曼病。利什曼病的标准治疗方法是五价锑，但已经提出了其他几种针对耐药性的药物，包括两性霉素和米替福星。在这里，我们提出一例由热带乳杆菌引起的鼻腔受累的多重治疗耐药性皮肤粘膜利什曼病；多种治疗无法达到治愈，最终通过在葡甲胺锑酸盐（Glucantime）中加入沙利度胺来改善治愈。据我们所知，这是首次报道沙利度胺在人类中用于利什曼病的治疗。